TuisSVA • NASDAQ
add
Sinovac Biotech Ltd
Vorige sluiting
$6,47
Jaarwisseling
$22,40 - $28,18
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 60,67 m | — |
Bedryfskoste | 174,35 m | — |
Netto inkomste | -3,95 m | — |
Netto winsgrens | -6,51 | — |
Wins per aandeel | — | — |
EBITDA | -99,97 m | — |
Effektiewe belastingkoers | -5,26% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 10,57 mjd | — |
Totale bates | 12,90 mjd | — |
Totale aanspreeklikheid | 1,39 mjd | — |
Totale ekwiteit | 11,51 mjd | — |
Uitstaande aandele | 99,64 m | — |
Prys om te bespreek | 0,07 | — |
Opbrengs op bates | -2,60% | — |
Opbrengs op kapitaal | -2,83% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -3,95 m | — |
Kontant van bedrywe | -219,45 m | — |
Kontant van beleggings | 218,41 m | — |
Kontant van finansiering | -85,59 m | — |
Netto kontantverandering | -100,08 m | — |
Beskikbare kontantvloei | -78,38 m | — |
Meer oor
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Its COVID-19 vaccine was the target of a covert disinformation campaign by the US government and a promotional social media astroturfing campaign by the Chinese government. Wikipedia
HUB
Gestig
2001
Webwerf
Werknemers
3 037
